Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Public ClinicalTrials.gov record NCT05388058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial compares topical cannabidiol to placebo in improving chemotherapy-induced peripheral neuropathy, or painful sensations in your hands or feet due to chemotherapy. Peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Peripheral neuropathy caused by chemotherapy is called chemotherapy-induced peripheral neuropathy (CIPN). CIPN is commonly seen in patients receiving certain chemotherapy medications and is hard to treat. Medications commonly used to treat CIPN have limited benefits and may cause significant side effects. A small report showed that topical cannabidiol may help treat neuropathy in patients with diabetes. This study is being done to determine if cannabidiol cream can help improve the symptoms of CIPN.
Study identification
- NCT ID
- NCT05388058
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Interventions
- Cannabidiol Drug
- Placebo Administration Drug
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 9, 2022 (Actual)
- Primary completion
- Jul 14, 2023 (Actual)
- Completion
- Jul 28, 2023 (Actual)
- Last update posted
- Jan 16, 2026
2022 – 2023
United States locations
- U.S. sites
- 9
- U.S. states
- 1
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Health System Albert Lea | Albert Lea | Minnesota | 56007 | — |
| Fairview Grand Itasca Clinic and Hospital | Grand Rapids | Minnesota | 55744 | — |
| Fairview Range Medical Center | Hibbing | Minnesota | 55746 | — |
| Mayo Clinic Health System Mankato | Mankato | Minnesota | 56001 | — |
| Monticello Cancer Center | Monticello | Minnesota | 55362 | — |
| Fairview Northland Medical Center | Princeton | Minnesota | 55371 | — |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | — |
| Sanford Thief River Falls | Thief River Falls | Minnesota | 56701 | — |
| Sanford Worthington | Worthington | Minnesota | 56187 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05388058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05388058 live on ClinicalTrials.gov.